October 27, 2025
Global TAVR Leaders React to the PARADIGM Trial
In this video, learn more about the PARADIGM Trial and hear perspectives from several global TAVR leaders.
Anteris recently received regulatory clearance to commence the pivotal trial for the first-in-class biomimetic DurAVR® valve. The PARADIGM Trial is the first head-to-head TAVR trial of its kind. The trial will move beyond conventional endpoints of safety, efficacy, and hemodynamic performance, aiming to also uncover the clinical impact of restoring physiologic flow patterns. This global pivotal trial has the potential to shift the treatment paradigm for aortic stenosis and redefine what is possible with TAVR. In this video, members of the Anteris executive team and global TAVR leaders provide an overview of the unique study design, the valve, and what excites them about the data that will be collected in the trial.